Market Overview

Sequenom Says Genetic Test Predicts Progression Risk

Related SQNM
Sequenom Can't Go Back; Ladenburg Analysts Downgrade To Sell
Benzinga's Top Downgrades
Midday Gainers / Losers (Seeking Alpha)

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.

Posted-In: News FDA


Related Articles (SQNM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters